Stock Price
1.03
Daily Change
0.01 0.98%
Monthly
31.29%
Yearly
-44.32%
Q2 Forecast
1.00

RedHill Biopharma reported $4.48M in Selling and Administration Expenses for its fiscal quarter ending in March of 2024.





Selling And Administration Expenses Change Date
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
Cronos Group USD 17.35M 2.1M Mar/2026
RedHill Biopharma USD 4.48M 1.52M Mar/2024